Clinical trial BOS172738
A Phase 1 Study of BOS172738 in Patients with Advanced Solid Tumors with RET Gene Alterations including Non-Small Cell Lung Cancer (NSCLC) and Medullary Thyroid Cancer (MTC)
| Cancers | |
|---|---|
| Organ | Multiple |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | Boston pharmaceuticals |
| EudraCT Identifier | 2018-002612-27 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03780517 |
| Inclusion criteria | Rearranged during transfection(RET) gene altered malignancy |
| Last update |